A Guide for Discussing Your Decentralized Trial Strategy with Your CRO
Eight Parameters to Achieve Site- and Patient-Centric Decentralized Trial Capabilities Disruptions preventing or limiting clinical trial site access to patien...
Executive Abstract
Disruptions preventing or limiting clinical trial site access to patients, monitors, and CRAs are propelling long-lasting changes in the research industry, supported by the adoption of trial virtualization technologies. The urgency to adapt to evolving requirements for both patients and sites is prompting sponsors to engage in new discussions with their CROs.
This guide provides eight parameters to help sponsors optimize their path to virtualization across key site- and patient-centric capabilities.
Unlock Report Access
Complete this brief form for instant PDF access.
Related Executive Research
White Paper
Electronic Clinical Outcome Assessments (eCOA) in Clinical Trials: A Review of Changing Trends
Speed Study Start-up and Facilitate Global COA Data Collection with eCOA Implementing electronic Clinical Outcome Assessments (eCOA) has become core to adaptin...
Guide
FDA Readiness Toolkit for Pharmaceutical Companies
Quality standards are defined by governing entities like the FDA in order to promote and sustain the quality of pharmaceutical products manufactured throughout...
eBook
Getting the Most Out of Your Unified Clinical Platform
A unified clinical trial platform enhances collaboration, monitoring, and analytics for even the most complex trials. Now more than ever, life sciences compani...